
The FDA approved adrabetadex for infantile-onset NPC based on a 55% lower risk of death vs external controls, with a boxed warning for hearing loss.
Pediatric vaccines have been much in the news recently, with new FDA approvals and the release of data on immunization coverage as of 2002 by the National Immunization Program (NIP) of the CDC.






